Krystal Biotech shares KB801 single-patient data
Krystal Biotech, Inc. reported that on July 21, 2026 it submitted a response to a U.S. Patent and Trademark Office Office Action for a published patent application covering KB801, its investigational gene therapy for neurotrophic keratitis.
Rhea-AI Filing Summary
Krystal Biotech, Inc. reported that on July 21, 2026 it submitted a response to a U.S. Patent and Trademark Office Office Action for a published patent application covering KB801, its investigational gene therapy for neurotrophic keratitis. The response includes data from a single patient in a discontinued clinical study who, after receiving KB801, experienced complete closure of a persistent corneal epithelial defect. The study was discontinued to advance KB801 into a pivotal trial, and no safety concerns or serious adverse events were observed in patients treated in that study.
Krystal Biotech explains that this single-patient observation had not been previously shared and is being disclosed so investors and other stakeholders have equal access to information that will appear in the patent prosecution record. The company emphasizes that this anecdotal result is not top-line data from any clinical trial and that no conclusions about the safety or efficacy of KB801 should be drawn from it. Krystal Biotech does not plan to provide subject-level updates from the discontinued study and expects to report pivotal trial results in the ordinary course. The described information and an image of the defect closure, furnished as an exhibit, are treated as furnished rather than filed under the Exchange Act and are not incorporated into other SEC reports except by specific reference, and the company notes forward-looking statements remain subject to clinical and other risks outlined in its risk factor disclosures.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Terms
Office Action, neurotrophic keratitis, pivotal trial, corneal epithelial defect, +1 more
5 terms
Office Action regulatory
"filed with the U.S. Patent and Trademark Office a response to an Office Action"
neurotrophic keratitis medical
"KB801, the Company’s investigational gene therapy product candidate for the treatment of neurotrophic keratitis"
A degenerative eye disease in which damage to the nerves that supply the cornea prevents normal healing, causing persistent surface breakdown, ulcers, scarring and potential vision loss. Think of it like a cut on the skin that you cannot feel and that doesn’t close because the repair signals are missing. It matters to investors because it defines patient populations, clinical trial endpoints, regulatory pathways and market need for therapies that restore corneal sensation or promote healing.
pivotal trial medical
"The Company discontinued the clinical study in order to advance KB801 into a pivotal trial"
A pivotal trial is a key test of a new medicine or treatment to see if it works and is safe enough to be approved by health authorities. It's like a final exam for a new product, and passing it is essential for bringing the treatment to the public.
corneal epithelial defect medical
"experienced complete closure of a persistent corneal epithelial defect"
patent prosecution record regulatory
"as it becomes publicly available through the patent prosecution record"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Krystal Biotech (KRYS) disclose about KB801 on July 21, 2026?
Krystal Biotech disclosed that a single neurotrophic keratitis patient in a discontinued KB801 study experienced complete closure of a persistent corneal epithelial defect, and that this anecdotal result was included in a patent Office Action response submitted to the U.S. Patent and Trademark Office.
What is KB801 and what condition is Krystal Biotech (KRYS) targeting?
KB801 is Krystal Biotech’s investigational gene therapy product candidate intended to treat neurotrophic keratitis. The company is advancing KB801 from a discontinued early study into a pivotal trial and has submitted related data in support of patentability for a published patent application.
What clinical observation was reported for the single KB801-treated patient at Krystal Biotech (KRYS)?
A patient with neurotrophic keratitis who received KB801 experienced complete closure of a persistent corneal epithelial defect. Krystal Biotech also reports that no safety concerns or serious adverse events were observed in patients treated in that discontinued clinical study.
Why was the KB801 clinical study discontinued by Krystal Biotech (KRYS)?
Krystal Biotech states the KB801 clinical study was discontinued to advance KB801 into a pivotal trial. The company plans to report results from this pivotal trial in the ordinary course rather than providing additional subject-level updates from the discontinued study.
How does Krystal Biotech (KRYS) describe the significance of the KB801 single-patient data?
Krystal Biotech emphasizes that the observation reflects the experience of a single patient, does not represent top-line results of any clinical trial, and that no conclusions regarding safety or efficacy of KB801 should be drawn from this anecdotal result.
How is this KB801 information treated under SEC rules for Krystal Biotech (KRYS)?
The company states the KB801 information and the image exhibit are furnished, not filed, under the Exchange Act, are not subject to Section 18 liabilities, and are not incorporated into other SEC reports except where expressly referenced by specific incorporation language.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 21, 2026
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
| (Address of principal executive offices) | (Zip Code) | |||||||||||||
Registrant’s telephone number, including area code (412 ) 586-5830
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
| Common Stock | KRYS | Nasdaq Global Select Market | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Item 8.01 Other Events.
On July 21, 2026, Krystal Biotech, Inc. (the “Company”) filed with the U.S. Patent and Trademark Office a response to an Office Action in connection with a published patent application relating to KB801, the Company’s investigational gene therapy product candidate for the treatment of neurotrophic keratitis. In support of the patentability of the claims, the response included data from a patient who received KB801 in a discontinued clinical study and experienced complete closure of a persistent corneal epithelial defect. The Company discontinued the clinical study in order to advance KB801 into a pivotal trial and no safety concerns or serious adverse events were observed in patients treated in the study.
The Company did not previously disclose the single-patient observation described above and is making this disclosure now solely to ensure that all investors and other stakeholders have equal access to it as it becomes publicly available through the patent prosecution record.
The observation described above reflects the experience of a single patient, does not represent top-line results of any clinical trial, and no conclusions regarding the safety or efficacy of KB801 should be drawn from it. The Company does not currently intend to provide subject-level updates from the discontinued clinical study and expects to report results from its pivotal trial of KB801 in the ordinary course.
The information in this Item 8.01 and the copy of the image of the corneal epithelial defect closure from the patent prosecution record that is attached to this Current Report on Form 8-K as Exhibit 99.1 shall not be (i) deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended , or otherwise subject to the liabilities of that section, or (ii) incorporated by reference into any filing with the Securities and Exchange Commission by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the timing of reporting results from the Company’s pivotal trial of KB801. Forward-looking statements are subject to known and unknown risks and uncertainties, including that results from a single patient or a discontinued study are not necessarily indicative of results in any pivotal or other trial, and the other risks and uncertainties described under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and its subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update any forward-looking statement, except as required by law.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit No. | Description | |||||||
| 99.1 | Image of corneal epithelial defect closure from patent prosecution record (furnished herewith) | |||||||
| 104 | Cover Page Interactive Data file (embedded within the Inline XBRL document) | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: | KRYSTAL BIOTECH, INC. | |||||||||||||||||||
| By: | /s/ Krish S. Krishnan | |||||||||||||||||||
| Name: | Krish S. Krishnan | |||||||||||||||||||
| Title: | Chairman and Chief Executive Officer | |||||||||||||||||||
